Advertisement
U.S. markets closed
  • S&P 500

    5,088.80
    +1.77 (+0.03%)
     
  • Dow 30

    39,131.53
    +62.42 (+0.16%)
     
  • Nasdaq

    15,996.82
    -44.80 (-0.28%)
     
  • Russell 2000

    2,016.69
    +2.85 (+0.14%)
     
  • Crude Oil

    76.57
    -2.04 (-2.60%)
     
  • Gold

    2,045.80
    +15.10 (+0.74%)
     
  • Silver

    22.98
    +0.19 (+0.84%)
     
  • EUR/USD

    1.0823
    -0.0005 (-0.04%)
     
  • 10-Yr Bond

    4.2600
    -0.0670 (-1.55%)
     
  • GBP/USD

    1.2673
    +0.0015 (+0.12%)
     
  • USD/JPY

    150.4400
    -0.0600 (-0.04%)
     
  • Bitcoin USD

    51,140.96
    +142.12 (+0.28%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,706.28
    +21.79 (+0.28%)
     
  • Nikkei 225

    39,098.68
    +836.48 (+2.19%)
     

TTY Biopharm Executive Outlines Strategies for Advancing Taiwan's mRNA Research

Identifying Needs, Building Partnerships, and Government Collaboration

TAIPEI, Aug. 18, 2023 /PRNewswire/ -- In light of the global awareness brought on by the coronavirus pandemic regarding the potential of mRNA drugs and lipid nanoparticles (LNPs) on human immunity, industry leaders are recognizing LNP technology's ability to enhance mRNA drug delivery. The improvement in efficiency is heralding a new frontier in prevention and treatment options, positioning LNPs as a groundbreaking new generation of therapeutic agents.

CEO of TTY Biopharm (4105-TW) Sara Hou with the 5th Tang Prize laureates in Biopharmaceutical Science - Katalin Karikó and Drew Weissman (PRNewsfoto/TTY BIOPHARM)
CEO of TTY Biopharm (4105-TW) Sara Hou with the 5th Tang Prize laureates in Biopharmaceutical Science - Katalin Karikó and Drew Weissman (PRNewsfoto/TTY BIOPHARM)

With these emerging opportunities in mind, the Tang Prize Foundation hosted the Tang Prize Taiwan Biotechnology Forum, inviting 5th Tang Prize laureates in Biopharmaceutical Science, Katalin Karikó, Drew Weissman and Pieter Cullis, to explore the evolving landscape of mRNA technologies with Distinguished Research Fellow at the Institute of Biological Chemistry at Academia Sinica (AS) Andrew H.-J. Wang, Deputy Minister of the National Science and Technology Council (NSTC) Yi-Juang Chern, and CEO of TTY Biopharm Sara Hou. Ms. Hou, a key voice in the industry, articulated three pivotal areas of focus: addressing unmet medical needs, forging strategic partnerships, and securing government support.

Professor Wang outlined AS's strategic direction, revealing the establishment of a dedicated research team and the construction of a GMP pilot facility to pioneer new technologies. Offering valuable insights, Weissman, with his robust experience in orchestrating GMP manufacturing plants across various regions, serves as a consultant to the initiative.

TTY Biopharm, a leader in liposome technology, joined the roster of participants at the forum. To advance mRNA drug development, Ms. Hou emphasized the initial necessity of identifying unmet clinical needs, including those related to the treatment of cancers and rare diseases. Furthermore, she stressed the increasing importance of fostering multi-party strategic collaborations, particularly in an increasingly competitive market environment that demands shorter time-to-market. Lastly, she underscored the crucial role of government intervention to unify and facilitate necessary resources, regulations and platforms.

In her closing remarks, Ms. Hou emphasized that by taking an integrated approach encompassing industry, government and academia, Taiwan has the potential to accelerate the research and development (R&D) and market introduction of innovative new medicines, not only transforming patient outcomes, but also elevating Taiwan's standing in the global biotechnology arena.

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/tty-biopharm-executive-outlines-strategies-for-advancing-taiwans-mrna-research-301904421.html

SOURCE TTY BIOPHARM

Advertisement